Compare SABS & OPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SABS | OPRT |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | 86 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.8M | 238.8M |
| IPO Year | N/A | 2019 |
| Metric | SABS | OPRT |
|---|---|---|
| Price | $3.85 | $5.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $10.75 | $7.00 |
| AVG Volume (30 Days) | ★ 996.7K | 365.0K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 127.18 |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $956,685,000.00 |
| Revenue This Year | N/A | $32.79 |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | ★ N/A | $108.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $4.03 |
| 52 Week High | $6.60 | $7.73 |
| Indicator | SABS | OPRT |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 53.45 |
| Support Level | $3.54 | $5.51 |
| Resistance Level | $4.11 | $5.68 |
| Average True Range (ATR) | 0.35 | 0.28 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 37.74 | 54.65 |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.